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Confounding factors of 
ultrafiltration and protein analysis 
in extracellular vesicle research
Glenn Vergauwen1,5,9, Bert Dhondt1,6,9, Jan Van Deun  1,9, Eva De Smedt7,9, Geert Berx7,9, 
Evy Timmerman2,3, Kris Gevaert2,3, Ilkka Miinalainen8, Véronique Cocquyt4,9, Geert Braems5,9, 
Rudy Van den Broecke5,9, Hannelore Denys4,9, Olivier De Wever1,9 & An Hendrix1,9
Identification and validation of extracellular vesicle (EV)-associated biomarkers requires robust 
isolation and characterization protocols. We assessed the impact of some commonly implemented 
pre-analytical, analytical and post-analytical variables in EV research. Centrifugal filters with different 
membrane types and pore sizes are used to reduce large volume biofluids prior to EV isolation or to 
concentrate EVs. We compared five commonly reported filters for their efficiency when using plasma, 
urine and EV-spiked PBS. Regenerated cellulose membranes with pore size of 10 kDa recovered 
EVs the most efficient. Less than 40% recovery was achieved with other filters. Next, we analyzed 
the effect of the type of protein assays to measure EV protein in colorimetric and fluorometric kits. 
The fluorometric assay Qubit measured low concentration EV and BSA samples the most accurately 
with the lowest variation among technical and biological replicates. Lastly, we quantified Optiprep 
remnants in EV samples from density gradient ultracentrifugation and demonstrate that size-exclusion 
chromatography efficiently removes Optiprep from EVs. In conclusion, choice of centrifugal filters 
and protein assays confound EV analysis and should be carefully considered to increase efficiency 
towards biomarker discovery. SEC-based removal of Optiprep remnants from EVs can be considered for 
downstream applications.
Extracellular vesicles (EVs), nanometer-sized vesicles secreted by different cell types, gained more interest over 
the last decade as important key players in intercellular communication1 and are a promising source for new 
biomarkers in cancer2–4. Despite extensive research concerning EVs in multiple body fluids (plasma, serum and 
urine among others), none of the identified biomarkers are yet clinically implemented. This can partially be attrib-
uted to inter- and even intra-laboratory variations in analytical variables that hamper reproducibility. Multiple 
efforts have been made to standardize EV research5–10. Identified EV-related functions and compositions vary 
depending on the implemented isolation method11, 12. Different anticoagulants prevent with variable efficiency in 
vitro activation of cells in blood collection tubes leading to vesiculation7, 13.
Centrifugal filters are implemented in 20% of EV isolation protocols described in the literature14 
(Supplementary Fig. 1). They are available with different membrane types and multiple pore sizes. The most 
frequently used membrane type is regenerated cellulose with a pore size of 100 kDa. Respectively 15% and 19% of 
studies do not specify membrane type and pore size of implemented centrifugal filters. Centrifugal filters are typ-
ically added to the EV isolation protocol to reduce large volume biofluids prior to EV isolation15 or to concentrate 
isolated EVs, for example after size-exclusion chromatography16–18. In addition, ultrafiltration using centrifugal 
filters is sometimes implemented to isolate EVs from biofluids19, 20.
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Quantitative EV treatments in cell culture or animal models are often expressed as µg protein or number of 
particles. The influence of choice of particle quantification method (eg. nanoparticle tracking analysis, tunable 
resistive pulse sensing, high-resolution flowcytometry) to assess EV numbers have been reported21, 22. Diverse 
buffers are known to lyse EVs with different efficiency and as such influence the estimated protein concentra-
tion23. Multiple protein assays are available, with BCA and Bradford being the most commonly implemented to 
measure EV protein concentration (Supplementary Fig. 2). 35% of EV-related publications do not report on the 
implemented protein assay14.
Optiprep is a non-ionic iso-osmotic contrast agent that is used for creating continuous density gradients24 
and effectively isolates high purity EVs from multiple body fluids11, 25–27. As a result, an increasing number of 
research groups implement Optiprep density gradient ultracentrifugation as validation or isolation method in 
their experiments14. EV samples obtained by Optiprep density gradient had higher functional activity compared 
to other isolation methods28. Interference of Optiprep with downstream omics approaches has not been reported.
In this manuscript we evaluate the effect of ultrafiltration procedures to concentrate large volume biofluids 
before EV isolation or to concentrate EVs after isolation. We investigate the effect of centrifugal filters and protein 
assays on EV samples and downstream EV analysis. In addition, we quantify Optiprep remnants in pelleted EVs 
obtained by Optiprep density gradient ultracentrifugation and suggest a protocol adjustment to remove Optiprep 
remnants from EV samples.
Material and Methods
Antibodies. Following antibodies were used for immunostaining: anti-green fluorescent protein (GFP) 
(1:1000, MAB3580, Merck Millipore, Billerica, Massachusetts, USA), anti-Syntenin-1 (1:1000, ab133267, 
Abcam, Cambridge, UK), anti-Flotillin-1 (1:1000, 610820, BD Biosciences, Franklin Lakes, New Jersey, USA), 
anti-Ago2 (1:1000, ab32381, Abcam, Cambridge, UK), anti-Alix (1:1000, 2171 S, Cell Signaling Technology, 
Beverly, Massachusetts, USA), anti-CD81 (1:1000, SC-166029, Santa Cruz Biotechnology, Dallas, Texas, USA), 
anti-TSG101 (1:1000, SC-7964, Santa Cruz Biotechnology, Dallas, Texas, USA), anti-Tamm-Horsfall (1:1000, 
SC-20631,, Santa Cruz Biotechnology, Dallas, Texas, USA), anti-ApoA-1 (1:1000, SC-376818, Santa Cruz 
Biotechnology, Dallas, Texas, USA), anti-albumin (1:1000, an28405, Abcam, Cambridge, UK), anti-IgG (1:1000, 
ab181236, Abcam, Cambridge, UK), anti-PMP70 (1:250, P0497, Sigma-Aldrich, St. Louis, Missouri, USA), sheep 
anti-mouse horseradish peroxidase-linked antibody (1:3000, NA931V, GE Healthcare Life Sciences, Uppsala, 
Sweden), donkey anti-rabbit horseradish peroxidase-linked antibody (1:4000, NA934V, GE Healthcare Life 
Sciences, Uppsala, Sweden).
Body fluids. Venous blood from breast cancer patients was collected using Venosafe-citrate tubes 
(VF-054SBCS07, Terumo Europe, Leuven, Belgium). Within 120 minutes after collection, whole blood was cen-
trifuged for 15 min at 2,500 g and room temperature, resulting in platelet poor plasma (PPP). To obtain platelet 
free plasma (PFP), PPP was centrifuged for 15 min at 2,500 g and room temperature. Plasma (PFP) was stored 
at −80 °C until further use. First morning urine was collected from bladder cancer patients and centrifuged 
for 10 minutes at 1,000 g and 4 °C, followed by storage at −80 °C until further use. Informed consent from all 
study patients was obtained prior to sample collection. Collection of patient samples was according to Ethical 
Committee of Ghent University Hospital approval and in accordance to relevant guidelines.
Cell culture. The MCF-7 cell line (ATCC, Manassas, Virginia, USA) was stably transfected with peGFP-C1 
vector (Clontech, Mountain View, California, USA) containing the Rab27b-GFP fusion protein, as previously 
described29. MCF-7 Rab27b-GFP cells were cultured in Dulbecco’s Modified Eagle Medium supplemented 
(DMEM) with 10% fetal bovine serum, 100 U/mL penicillin, 100 µg/mL streptomycin and 1 mg/mL G418. 
Presence of Mycoplasma contamination was routinely tested using MycoAlert Mycoplasma Detection Kit (Lonza, 
Verviers, Belgium).
Preparation of conditioned medium for EV isolation. To prepare conditioned medium (CM), 4 × 108 
MCF-7 Rab27b-GFP cells were washed once with DMEM, followed by two washing steps with DMEM supple-
mented with 0.5% EV-depleted fetal bovine serum (EDS). EDS was obtained after 18 hours ultracentrifugation 
at 100,000 g and 4 °C (SW55 Ti rotor, Beckman Coulter, Fullerton, California, USA), followed by 0.22 µm filtra-
tion. Flasks were incubated at 37 °C and 10% CO2 with 15 mL DMEM containing 0.5% EDS. After 24 h CM was 
collected and centrifuged for 10 min at 200 g and 4 °C. Cell counting was performed with trypan blue staining 
to assess cell viability (Cell Counter, Life Technologies, Carlsbad, California, USA). The supernatant was passed 
through a 0.45 µm cellulose acetate filter (Corning, New York, USA) and CM was concentrated at 4 °C approxi-
mately 250 times using a 10 kDa Centricon Plus-70 centrifugal unit (Merck Millipore, Billerica, Massachusetts, 
USA). After filtering through a 0.22 µm filter (Whatman, Dassel, Germany), concentrated conditioned medium 
(CCM) was used for Optiprep density gradient ultracentrifugation.
Optiprep density gradient. Optiprep (Axis-Shield, Oslo, Norway) density gradients were prepared as 
previously described11. Briefly, a discontinuous iodixanol gradient was prepared by layering 4 mL of 40%, 4 mL 
of 20%, 4 mL of 10% and 3.5 mL of 5% iodixanol in a 16.8 mL open top polyallomer tube (Beckman Coulter, 
Fullerton, California, USA). One milliliter of CCM or phosphate-buffered saline (PBS) was placed on top of the 
gradient, followed by 18 h ultracentrifugation at 100,000 g and 4 °C using SW 32.1 Ti rotor (Beckman Coulter, 
Fullerton, California, USA). Fractions of 1 mL were collected and EV-rich fractions 8 and 9 were pooled (cor-
responding to a density of ~1.1 g/ml). Pooled fractions were diluted to 15 mL with PBS, followed by 3 h ultra-
centrifugation at 100,000 g and 4 °C using SW 32.1 Ti rotor (Beckman Coulter, Fullerton, California, USA). 
Resulting pellets were resuspended in 100 µL PBS and stored at −80 °C until further use. When indicated, 3 h 
ultracentrifugation was replaced by size-exclusion chromatography. The obtained GFP-positive EVs were used 
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in the experiments and further on referred to as ‘EVs’. Characterization of implemented EVs can be found in 
Supplementary Fig. 3. EV isolation and analysis details are submitted to EV-TRACK (http://evtrack.org).
EV-TRACK ID: EV170001 (EV-METRIC 100%).
Size-exclusion chromatography. Sepharose CL-2B (GE Healthcare, Uppsala, Sweden) was washed three 
times with PBS containing 0.32% trisodiumcitrate dihydrate (ChemCruz, Dallas, Texas, USA). For preparation 
of one column, nylon net with 20 µm pore size (NY2002500, Merck Millipore, Billerica, Massachusetts, USA) was 
placed on bottom of a 10 mL syringe (BD Biosciences, San Jose, California, USA), followed by stacking of 10 mL 
Sepharose CL-2B. On top of the SEC column, 2 mL of sample was loaded and fractions of 1 mL eluate were col-
lected. Resulting fractions were stored at −80 °C.
Ultrafiltration. Five different centrifugal filters were used: Amicon Ultra-2 10k (UFC201024, Merck 
Millipore, Billerica, Massachusetts, USA), Amicon Ultra-2 100k (UFC210024, Merck Millipore, Billerica, 
Massachusetts, USA), Vivaspin 2 PES 10k (VS0201, Sartorius Stedim Biotech GmbH, Goettingen, Germany), 
Vivaspin 2 CTA 10k (VS02V1, Sartorius Stedim Biotech GmbH, Goettingen, Germany) and Vivaspin 2 Hydrosart 
10k (VS02H01, Sartorius Stedim Biotech GmbH, Goettingen, Germany). 2 mL PBS spiked with 2 × 1010 EVs was 
centrifuged at 3,000 g and 4 °C (duration: 10–20 min) using a swinging bucket rotor. Concentrated samples were 
retrieved by upside-down centrifugation at 1,000 g and 4 °C (duration: 2 min). Eluates were collected from the 
flow-through reservoir. Membrane lysates were obtained by repetitive washing of the membranes with 0.4% SDS.
Nanoparticle tracking analysis. Aliquots of isolated EVs were used for nanoparticle tracking analysis 
(NTA) using the NanoSight LM10 microscope (Malvern Instruments Ltd, Malvern, UK) equipped with a 455 nm 
laser. For each sample, three videos of 60 seconds were recorded and analyzed with camera level 13 and detection 
threshold 3. Temperature was monitored during recording. Recorded videos were analyzed with NTA Software 
version 3.2. For optimal measurements, samples were diluted with PBS until particle concentration was within 
optimal concentration range of the NTA Software (3 × 108–1 × 109).
Electron microscopy. Aliquots of EVs were used for transmission electron microscopy. Sample was depos-
ited on Formvar carbon-coated, glow discharged grids. Grids were stained with uranylacetate and embedded in 
methylcellulose/uranylacetate. Prepared grids were examined using a Tecnai Spirit transmission electron micro-
scope (FEI, Eindhoven, The Netherlands) and images were captured with Quemasa charge-coupled device cam-
era (Olympus Soft Imaging Solutions GMBH, Munster, Germany).
Western blot. All samples were dissolved in reducing sample buffer (0,5 M Tris-HCl (pH 6.8), 40% glyc-
erol, 9,2% SDS, 3% 2-mercaptoethanol, 0.005% bromophenol blue) and boiled at 95 °C for 5 min. Proteins were 
separated by SDS-polyacrylamide gel electrophoresis and transferred to nitrocellulose membranes (Bio-Rad, 
Hercules, California, USA). After blocking the membranes, blots were incubated overnight with primary anti-
bodies. Incubation with secondary antibodies was performed after extensive washing of the membranes in PBS 
containing 0,5% Tween 20. After final washing, chemiluminescence substrate (WesternBright Sirius, Advansta, 
Menlo Park, California, USA) was added and imaging was performed using Proxima 2850 Imager (IsoGen Life 
Sciences, De Meern, The Netherlands). Quantification of signal intensity was performed using ImageJ software.
TRIFic exosome assay. Quantification of CD9 was performed using the TRIFic exosome assay (Cell 
Guidance Systems, Carlsbad, California, USA) according to manufacturer’s protocol. Briefly, a 96-well plate was 
coated with the capture CD9 antibody, followed by addition of the samples in the 96-well plate. Europium-labeled 
detection CD9 antibody was added afterwards. Each step extensive washing was performed. Signal enhance-
ment solution was added and fluorescence was measured. Results were obtained using the Paradigm Detection 
Platform (Beckman Coulter, Fullerton, California, USA) using SoftMax Pro 6.1 software (Molecular Devices, 
Sunnyvale, California, USA).
Optiprep quantification based on Lowry interference. Quantification of residual Optiprep was based 
on the observed interference of iodixanol with Lowry-based protein measurement. A dilution series of 0 to 10% 
of Optiprep in PBS was obtained as a standard curve for performing absorbance readings with DC Protein assay 
(Bio-Rad, Hercules, California, USA), according to manufacturer’s instructions. Pelleted Optiprep fractions 8–9 
of blank gradients were used as sample for measuring absorbance. Calculations of Optiprep were made using 
the previouly described Optiprep dilution series as standard curve. Readings were performed on the Paradigm 
Detection Platform (Beckman Coulter, Fullerton, California, USA) using SoftMax Pro 6.1 software (Molecular 
Devices, Sunnyvale, California, USA).
Protein quantification assays. Seven different protein assays were compared. In all assays, 5 µL of EVs 
(lysing condition SDS 0.2%) derived from the MCF-7 Rab27b-GFP cell line were used as sample. According 
to manufacturer’s instructions, the 5 µL sample was diluted with PBS to assay sample volume. The microplate 
protocol in assay-specific datasheet was performed using following protein assays: DC Protein assay (Bio-Rad, 
Hercules, California, USA), Pierce BCA protein assay (Life Technologies, Carlsbad, California, USA), Coomassie 
Plus Bradford assay (Life Technologies, Carlsbad, California, USA) and MicroBCA protein assay (Life 
Technologies, Carlsbad, California, USA). Two fluorometric assays were performed according to manufactur-
er’s instructions: NanoOrange (Life Technologies, Carlsbad, California, USA) and FluoroProfile (Sigma-Aldrich, 
St. Louis, Missouri, USA). Absorbance and fluorescence readings were obtained using the Paradigm Detection 
Platform (Beckman Coulter, Fullerton, California, USA) using SoftMax Pro 6.1 software (Molecular Devices, 
Sunnyvale, California, USA). A third fluorometric assay was used: Qubit Protein assay kit (ThermoFisher, 
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Waltham, Massachusetts, USA), measurements were performed using the Qubit Fluorometer 3.0 (ThermoFisher, 
Waltham, Massachusetts, USA).
RNA extraction and RT-qPCR. RNA was extracted using miRNeasy micro kit (Qiagen, Valencia, 
California, USA), according to manufacturer’s instructions. RNA was reverse transcribed to cDNA with Sensifast 
cDNA Synthesis Kit (GC Biotech, Alphen aan den Rijn, The Netherlands). RT-qPCR for gene expression anal-
ysis was performed using SensiFast SYBR No-Rox kit (GC Biotech, Alphen aan den Rijn, The Netherlands) on 
LightCycler 480 (Roche, Brussels, Belgium). The used primers can be found in Supplementary Table 1. Gene 
expression was assessed relatively to initial spike-in RNA amount. Analysis was performed using qBase + soft-
ware 3.0 (Biogazelle, Ghent, Belgium).
Statistical analysis. Data analysis and graphical presentations were performed using GraphPad Prism ver-
sion 7.02 (Graphpad Software, San Diego, California, USA). An unpaired Student’s t-test was applied for deter-
mination of significant difference between conditions. P values of less than 0.05 indicated statistical significance. 
Data are expressed as mean ± SD.
Results
Impact of centrifugal filters on particle and protein recovery from biofluids. The efficiency of 
five different centrifugal filters was compared to concentrate a defined number of isolated EVs spiked in PBS 
(1010 EVs/mL): Amicon 100k RC, Amicon 10k RC, Vivaspin 10k HY, Vivaspin 10k PES and Vivaspin 10k CTA 
(Table 1). For each column, 2 mL sample was concentrated 20-fold (100 µL) by centrifugation at 3,000 g and 
4 °C. Three end-point samples per column were analyzed: the concentrate, the filtrate and the membrane lysate 
(Fig. 1a). These samples were analyzed by NTA, electron microscopy, protein concentration measurement, 
Western blot analysis and/or RT-qPCR.
Amicon 10k RC generated the highest particle and protein recovery ([particle or protein concentration 
after centrifugation/particle or protein concentration before centrifugation] * 100) of EVs in the concentrate 
(Fig. 1b,c). Amicon 100k RC recovered significantly less EVs as compared to Amicon 10k RC. Other centrifugal 
membranes (Vivaspin 10k HY, Vivaspin 10k PES and Vivaspin 10k CTA) did not efficiently recover EVs in the 
concentrate with up to 80% reduction in particle concentration and protein concentration measurements below 
detection threshold. Size distribution profiles and electron microscopy images of concentrated EV samples are 
summarized in Supplementary Fig. 4. NTA measurements of filtrates for all centrifugal filters were below detec-
tion threshold, excluding passage of EVs through the membrane pores (data not shown).
Protein concentration was above detection threshold for all lysates of the membranes of the centrifugal filters, 
except for the Amicon 10k RC where no protein was detected (Fig. 1d). Western blot analysis for GFP of both the 
concentrate and the membrane lysate showed that EVs were retained in the concentrate using the Amicon 10k 
RC, with the absence of EVs in the membrane lysate. By contrast, for all the other centrifugal filters, the majority 
of EVs are recovered in the membrane lysate (Fig. 1e).
Influence of centrifugal filter on RNA analysis was studied by RT-qPCR for all different centrifugal filters. We 
selected four genes (NOP10, OST4, SNRPG, TOMM7) known to be present in EVs from MCF-7 breast cancer 
cells overexpressing Rab27b-GFP11. For all four genes, identical observations were made as with particle and 
protein analysis, where Amicon 10k RC showed the highest RNA signal compared to the other centrifugal filters 
(Fig. 2).
Next, the centrifugal filters were applied to two commonly used body fluids: plasma and urine. The concen-
trate, retrieved after centrifugation at 3,000 and 4 °C (duration 20–40 min), was analyzed by NTA, protein concen-
tration measurement and Western bot analysis (Fig. 3a). Since plasma is a protein-rich body fluid, size-exclusion 
chromatography was performed to obtain a protein-poor, EV-enriched fraction which was subsequently concen-
trated by ultrafiltration (Supplementary Fig. 5). The highest number of particles was obtained in the concentrate 
of Amicon 10k RC. Implementing Amicon 100k RC reduced particle recovery. However, the loss of particles was 
drastically higher in the concentrate from the other membranes (Fig. 3b). Analogous results were observed by 
measuring protein concentration. The highest protein recovery in the concentrate was obtained by using Amicon 
10k RC. These results were reflected on Western blot analysis for syntenin-1 (Fig. 3c). Also for urine, NTA showed 
the highest concentration of particles in the concentrate obtained by Amicon 10k RC (Fig. 3d), which was con-
firmed by protein recovery and syntenin-1 quantification (Fig. 3e). Western blot analysis of the membrane lysates 
identified soluble proteins and lipoproteins on all membranes, suggesting nonspecific binding of these proteins 
to the membranes (Supplementary Fig. 6).
In conclusion, centrifugal filters with a regenerated cellulose membrane with a pore size of 10 kDa are required 
to concentrate EVs without significant loss.
Membrane Pore size
Amicon 10k RC regenerated cellulose 10 kDa
Amicon 100k RC regenerated cellulose 100 kDa
Vivaspin 10k HY Hydrosart 10 kDa
Vivaspin 10k PES polyethersulfone 10 kDa
Vivaspin 10k CTA cellulose triacetate 10 kDa
Table 1. Characteristics of implemented centrifugal filters.
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Figure 1. Comparative analysis of centrifugal filters for protein and particle recovery of EVs in PBS. (a) 2 mL 
PBS spiked with GFP-positive EVs was centrifuged at 3,000 g. Concentrate and filtrate were collected. Lysates of 
filter membranes were used for analysing retained proteins. (b) Particle recovery was analyzed using Nanoparticle 
tracking analysis (n = 3, *p < 0.0001). (c) Protein recovery was assessed based on protein concentration 
measurements (n = 3, *p < 0.0001). (d) Retained proteins on the filter membrane were quantified (n = 3, 
*p < 0.0009). (e) Lysates were used for Western blot immunostaining for GFP. Mean values + SD are indicated. 
Significant differences were calculated using Student’s t-test with RC 10k as reference. Original immunostaining 
results are shown in Supplementary Fig. 10. Abbreviations: PBS: phosphate buffered saline. GFP: green 
fluorescent protein. EV: extracellular vesicle. RC: regenerated cellulose. HY: Hydrosart. PES: polyethersulfone. 
CTA: cellulose triacetate. WB: Western blot. NTA: Nanoparticle tracking analysis. PCM: protein concentration 
measurement. RT-qPCR: real time quantitative polymerase chain reaction. EM: electron microscopy.
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Impact of protein assays on the quantification of EV protein. The performance of four color-
imetric assays (DC Protein, BCA, MicroBCA, Bradford) and three fluorometric assays (Qubit, NanoOrange, 
FluoroProfile) was compared on three different sample types: a lysed EV sample and two BSA solutions with 
known concentrations (400 µg/mL and 200 µg/mL). Supplementary Table 2 indicates the main characteristics 
and differences between the implemented protein assays. In compliance with the manufacturer’s guidelines, a 
corresponding dilution was implemented to obtain the optimal sample volume for each individual assay (Fig. 4a). 
For all protein assays the same starting volume of 5 µL EVs was used, corresponding to 2 × 1010 particles. BSA, a 
protein commonly used as reference or internal standard in protein quantification methods, was used to assess 
variation in protein measurements between different protein assays. Measuring both low BSA concentrations 
(400 µg/mL and 200 µg/mL), we observed variation throughout the different protein assays, with least variance for 
the most accurate measurements by Qubit and DC Protein (Fig. 4b,c). Interference of Folin’s reagent, a main com-
ponent of DC Protein and all other Lowry-based protein assays, with iodixanol has previously been described24 
and thereby allows to quantify Optiprep remnants in EV pellets. We prepared a standard curve of Optiprep using 
the DC Protein assay (Supplementary Fig. 7a). The Optiprep concentration of pelleted EV density fractions from 
a blank Optiprep gradient (PBS as sample) was estimated at 1.5–2.5% (Supplementary Fig. 7b,c). Comparison of 
all seven protein assays for interference of Optiprep using a 3% Optiprep-containing PBS sample indicated major 
interference for the DC Protein assay (Supplementary Fig. 8). Due to this interference, further comparison of 
protein assays on EV samples were performed for all protein assays except the Lowry-based DC Protein assay.
Differences in protein concentration measurement were observed dependent upon the implemented pro-
tein assay (Fig. 5a,b). The Qubit assay obtained a respectively 1.5-fold and 2-fold higher protein concentration 
measurement as compared to MicroBCA and Bradford. The difference in obtained results was not due to inter-
ference of Optiprep, as shown in Fig. 5c. Protein concentration measurements of EV lysates before and after one 
freeze-thaw cycle revealed no significant difference within any assay (Supplementary Fig. 9).
Taken together, Qubit assay is able to accurately measure low BSA concentration with least variance compared 
to other protein assay kits. This low variance was also confirmed for EV samples, suggesting it to be a suitable 
assay for protein quantification.
Removal of Optiprep remnants in EV samples. To remove the previously mentioned Optiprep rem-
nants from EV samples, we investigated the use of size-exclusion chromatography as an alternative to 100,000 g 
Figure 2. Comparative analysis of centrifugal filters for EV-associated RNA recovery in PBS. Four genes 
present in EVs derived from MCF-7 Rab27b-GFP cell line were assessed using RT-qPCR. Results are expressed 
relatively to spike-in EV RNA level for (a) NOP10, (b) OST4, (c) SNRPG and (d) TOMM7. Triplicate 
experiments are indicated by three bars per condition. Mean values + SEM are indicated (n = 3). Abbreviations: 
PBS: phosphate buffered saline. EV: extracellular vesicle. RC: regenerated cellulose. HY: Hydrosart. PES: 
polyethersulfone. CTA: cellulose triacetate. RT-qPCR: real time quantitative polymerase chain reaction.
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Figure 3. Comparative analysis of centrifugal filters for protein and particle recovery from plasma and urine. 
(a) Blood plasma was loaded on SEC column and EV-rich fractions were concentrated using five different 
centrifugal filters. Urine was concentrated using the same type of filters. (b) Nanoparticle Tracking Analysis 
(n = 2, *p < 0.05) and (c) Western blot analysis for syntenin-1 was performed on concentrated EV-rich SEC-
fractions from plasma (n = 2, *p < 0.04). Western blot analysis was quantified using RC 10k as reference. (d) 
Concentrated urine was analyzed by Nanoparticle tracking analysis (n = 2, *p < 0.05) and (e) Western blot 
analysis for syntenin-1 (n = 2, *p < 0.02). Western blot analysis was quantified using RC 10k as reference in 
(c,e). Mean values + SD are indicated. Significant differences were calculated using Student’s t-test with RC 
10k as reference. Original immunostaining results are shown in Supplementary Fig. 10. Abbreviations: SEC: 
size-exclusion chromatography. EV: extracellular vesicle. RC: regenerated cellulose. HY: Hydrosart. PES: 
polyethersulfone. CTA: cellulose triacetate. WB: Western blot. NTA: Nanoparticle tracking analysis. PCM: 
protein concentration measurement.
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pelleting for 3 hours (Fig. 6a). Optiprep quantification in SEC fractions using the DC Protein assay was per-
formed and indicated that Optiprep elution starts from SEC fraction 8–9 onwards (Fig. 6b). The majority of EVs 
from EV-containing Optiprep density fractions prepared from cell culture supernatant elute in SEC fractions 4–7 
(Fig. 6b). Western blot immunostaining for GFP and CD9 quantification using an ELISA assay confirmed that the 
particles eluted in SEC fractions 4–7 were CD9 and GFP positive (Fig. 6c).
Figure 4. Comparison of the performance of different protein assays to measure protein concentration of BSA 
and EV samples. (a) Seven different protein assays (four colorimetric, three fluorometric) were compared using 
three different samples: BSA 400 µg/mL, BSA 200 µg/mL and EV sample. Identical sample volume was used 
in all assays and proper dilution to working sample volume was implemented. (b,c) All protein assays were 
performed on two known BSA concentrations: (b) 400 µg/mL (n = 3, *p < 0.003) and (c) 200 µg/mL (n = 3, 
*p < 0.05). Red dotted line indicates known BSA concentration. Mean values + SD are indicated. Significant 
differences were calculated using Student’s t-test with Qubit as reference. Abbreviations: EV: extracellular 
vesicle. BSA: bovine serum albumin. Exp.: Experiment.
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In conclusion, removal of Optiprep remnants in EV samples can be obtained by size-exclusion chromatogra-
phy as alternative of EV pelleting by ultracentrifugation at 100,000 g.
Discussion
Important yet undervalued sources of variability that impair reproducibility of EV results are identified. 
Ultrafiltration or centrifugal concentration are important steps in EV isolation protocols. Several companies offer 
centrifugal filters with different membrane types. The choice of centrifugal filter determines the recovery of EVs 
from samples. In addition, EV research papers do not adequately report the choice of ultrafiltration filter14. Both 
elements may severely impact the reproducibility of isolation protocols. The variability in recovery is due to 
different binding capacities of EVs to various membrane filters. Nonspecific binding of compounds to centrif-
ugal membranes has already been described30, yet for EV research this information was lacking. Treating the 
membranes with detergents reduced nonspecific binding of compounds to the membrane31 but resulting rem-
nant detergent is an obvious obstacle for EV isolation. Regenerated cellulose was shown to be the least adhesive 
membrane for EVs and thereby the most optimal membrane for handling EV samples. Moreover, not only type 
of filter membrane appeared important, but also the pore size influenced recovery. Regenerated cellulose mem-
branes with a 100 kDa pore size resulted in adhesion of EVs on the membrane, while this effect was not observed 
in a 10 kDa pore size membrane of regenerated cellulose. The differences between the centrifugal filters was lower 
when applied to plasma and urine as compared to the in vitro set-up with EVs spiked into PBS. This is likely due 
to the presence of soluble proteins and lipoproteins in body fluids that adhere to the membranes and thereby 
partially prevent EVs from binding to the membranes. However, despite the competitive nonspecific binding of 
proteins, still a substantial amount of EVs adhere to the filter membranes. Our data suggest to test different cen-
trifugal filters for different sample types prior to their implementation in ultrafiltration or concentration and to 
correctly report their use in materials and methods sections for optimal reproducibility of experiments between 
research groups.
Quantitative experiments (eg. recovery descriptions, functional assays in vitro and in vivo) are not only con-
founded by particle number21, 22, but also by protein quantification dependent on the type of protein assay kit 
used. Although within-kit measurements showed high repeatability, between-kit measurements resulted in major 
quantitative differences. If the type of protein assay is not reported in the materials and methods section, repro-
ducibility among research groups is hampered. Comparison studies of protein assays have been described pre-
viously32–34, yet this comparison for EV samples is still lacking. Kirazov et al. encountered underestimation of 
protein when membrane-containing samples were measured using Bradford assay33. In agreement, the Bradford 
Figure 5. Performance of different protein assays to measure protein concentration of EV samples. (a) 
Protein quantification for one EV sample using three colorimetric assays (MicroBCA, BCA, Bradford) was 
performed opposed to one fluorometric assay (Qubit) (n = 3, *p < 0.003). (b) All fluorometric assays (Qubit, 
FluoroProfile, NanoOrange) were tested on another EV-sample (n = 3, *p < 0.005). Mean values + SD are 
indicated. Significant differences were calculated using Student’s t-test with Qubit as reference. Abbreviations: 
EV: extracellular vesicle. BSA: bovine serum albumin.
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assay underestimated EV protein concentrations. Measuring protein content of outer membrane vesicles (OMVs) 
from bacteria had less variance using Lowry-based assay than using Bradford, again resulting in lower meas-
urements when using Bradford assay32. Comparison of six different protein assay kits indicated highly different 
results on analysis of EV samples, while this difference was present but less pronounced using BSA standards 
(200–400 µg/mL). The fluorometric assay Qubit showed the least variance between different experiments and was 
able to obtain results the closest to the known BSA concentrations. Given this accurate measurement, combined 
with the absence of multiple manipulations in the protocol or sample dilution, Qubit is a reproducible and easy 
method for protein quantification of EV samples.
Optiprep remnants in isolated EV pellets are between 1.5–3%. The importance of residual isolation matrix in 
obtained EVs has been decribed, showing Optiprep-isolated EVs to be more functionally active than those from 
eg. precipitation techniques28. This higher functional activity was attributed to the presence of residual matrix 
in the precipitation techniques. However, the influence of residual Optiprep was not investigated. Optiprep was 
removed from EV samples by SEC, as was already described for the isolation of adenoviral vectors35. Using DC 
Protein assay, based on interference of Optiprep with this Lowry-based protein assay, the removal of Optiprep 
from EVs was confirmed. The classic pelleting step at 100,000 g for 3 hours is replaced by a SEC step. SEC pre-
serves functional and biological activities of EVs36 and is, in contrast to ultracentrifugation, not known for induc-
ing aggregation of EVs37. Further knowledge of the benefit of Optiprep removal from EV samples still needs to 
be determined, especially regarding functional activity of isolated EVs and the impact on downstream omics 
approaches.
Figure 6. The implementation of size-exclusion chromatography to remove Optiprep remnants from EV 
samples. (a) Optiprep density gradients were loaded with PBS to obtain blank EV-density fractions (F1) and 
with CCM to obtain EV-containing fractions (F2). EVs were retrieved by pelleting at 100,000 g (P1) or by size-
exclusion chromatography (S1). Quantity of Optiprep in S1 and P1 was calculated using DC Protein assay. 
SEC was performed on F2 and consecutive SEC fractions (S2) were analyzed by NTA and protein analysis 
for GFP and CD9. (b) Comparative graph of NTA from S2 (connected line, marked area = SD) and Optiprep 
quantification of S1 (three differently colored bars representing three independent gradients, SD indicated). (c) 
Protein analysis of S2 by Western blot analysis for GFP and CD9 quantification by TRIFic CD9 assay. Original 
immunostaining results are shown in Supplementary Fig. 10. Abbreviations: PBS: phosphate buffered saline. 
CCM: concentrated conditioned medium. GFP: green fluorescent protein. EV: extracellular vesicle. WB: 
Western blot. NTA: Nanoparticle tracking analysis. SEC: size-exclusion chromatography.
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In conclusion, minor protocol parameters, such as type of centrifugal filter and type of protein assay, can 
have a major impact on data from EV experiments. In addition, when implementing Optiprep density gradient 
centrifugation, removal of Optiprep may be considered for downstream applications. It is crucial to report each 
protocol step properly to enhance reproducibility among research groups. Especially when working with a low 
amount of EVs, appropriate choices should be made to ensure optimal EV recovery, quantitative estimations and 
protein or RNA identification.
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